Low concentrations of doxycycline attenuates FasL-induced apoptosis in HeLa cells by unknown
Yoon et al. Biol Res  (2015) 48:38 
DOI 10.1186/s40659-015-0025-8
RESEARCH ARTICLE
Low concentrations of doxycycline 
attenuates FasL-induced apoptosis in HeLa cells
Jung Mi Yoon1†, Sushruta Koppula1†, Se Jong Huh1, Sun Jin Hur2 and Chan Gil Kim1*
Abstract 
Background: Doxycycline (DC) has been shown to possess non-antibiotic properties including Fas/Fas Ligand (FasL)-
mediated apoptosis against several tumor types in the concentration range of 10–40 µg/mL. However, the effect of 
DC in apoptotic signaling at much low concentrations was not studied.
Methods: The present study investigated the attenuation effect of low dose of DC on FasL-induced apoptosis in 
HeLa cell by the methods of MTT assay, fluorescence microscopy, DNA fragmentation, flow cytometry analysis, and 
western blotting.
Results and conclusion: In the present findings we showed that low concentration of DC (<2.0 µg/mL) exhibited 
protective effects against FasL-induced apoptosis in HeLa cells. FasL treatment to HeLa cells resulted in a concentra-
tion-dependent induction of cell death, and treatment with low concentrations of DC (0.1–2 µg/mL) significantly 
(p < 0.001) attenuated the FasL-induced cell death as measured by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) assay. Further, the FasL-induced apoptotic features in HeLa cells, such as morphological changes, 
DNA fragmentation and cell cycle arrest was also inhibited by DC (0.5 µg/mL). Tetracycline and minocycline also 
showed similar anti-apoptotic effects but were not significant when compared to DC, tested at same concentrations. 
Further, DC (0.01–16 µg/mL) did not influence the hydrogen peroxide- or cisplatin-induced intrinsic apoptotic path-
way in HeLa cells. Protein analysis using Western blotting confirmed that FasL-induced cleavage/activation of cas-
pase-8 and caspase-3, were inhibited by DC treatment at low concentration (0.5 µg/mL). Considering the overall data, 
we report for the first time that DC exhibited anti-apoptotic effects at low concentrations in HeLa cells by inhibition of 
caspase activation via FasL-induced extrinsic pathway.
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Background
Apoptosis is a regulated physiological process essential 
for maintaining cellular homeostasis [1, 2]. The signaling 
events leading to apoptosis can be divided into two major 
pathways, the intrinsic mitochondrial and extrinsic death 
receptors [3, 4]. It was well known that caspase activa-
tion is a crucial step at which cells become committed to 
undergo apoptosis [5, 6]. In intrinsic pathway, a variety of 
extracellular and intracellular stress stimuli converge at 
the mitochondrial level, resulting in the translocation of 
cytochrome c (Cyt c) from the mitochondria to the cyto-
plasm. Cyt c binds the cytosolic adapter protein Apaf-1, 
which allows the recruitment and activation of an ini-
tiator caspase caspase-9. Active caspase-9 then cleaves 
and activates procaspase-3. The ‘apoptosome’, a com-
plex formed by Cyt c, Apaf-1 and caspase-9, is a critical 
activator of effective caspase [7–12]. The mitochondrial 
apoptosis pathway is also partly regulated by the Bcl-2 
family of proteins. Bcl-2 family members may be pro-
apoptotic or anti-apoptotic [13].
Apoptosis mediated by extrinsic death receptors, such 
as Fas and FasL has been shown to play an important role 
in regulating apoptosis. Ligands bind to their cell surface 
receptors and through signaling transduction cascades, 
lead to the activation of an initiator caspase, caspase-8. 
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Once caspase-8 is activated, it can process effector cas-
pases such as caspase-3, -6, and -7, to induce a caspase 
signaling cascade [14–16]. Crosslinking of Fas with nat-
ural FasL initiates an apoptotic signal transduction cas-
cade leading to cell death [17]. 
Tetracyclines including minocycline (MIN) and doxy-
cycline (DC), in addition to their antimicrobial activities 
possess cytotoxic activity against several tumor cells [18, 
19]. Particularly, DC, a semi-synthetic tetracycline char-
acterized by the presence of a dimethylamino group at 
C4 and a hydroxy group at C5 is made by modifying the 
chemical structure of a naturally occurring tetracycline, 
so as to enhance its antibiotic activity. DC can inhibit 
MMP expression and cell proliferation in various types 
of cultured cell lines and in animal models [18, 20, 21]. 
DC-mediated anti-proliferative activity may be associ-
ated with the regulation of cell proliferation as well as its 
ability to inhibit MMP activity [20, 22]. Further, DC was 
also reported to induce apoptosis, decrease the invasion 
of tumor cells, and suppress the metastatic potential in 
breast cancer and melanoma cell lines at concentrations 
of 5–10 μg/mL [22, 23]. Thus, DC has been evaluated in 
preclinical cancer models and entered in early clinical tri-
als in patients with malignant diseases [24].
Recently, research has focused on the possible 
non-anti-microbial effects of tetracycline and its deriva-
tives, especially their anti-tumor functions such as inhi-
bition of solid malignant tumor proliferation, invasion, 
metastasis and as well as the induction of apoptosis in 
cultured tumor cells [25–28]. The ability of tetracyclines 
including DC, to induce apoptosis was well reported in 
osteosarcoma, prostatic cancer cells and Jurkat T lym-
phocytes [18, 20, 29].
On the other hand, there is an increasing body of evi-
dence suggesting that the tetracyclines possess anti-
apoptotic properties [30]. It was found that MIN and DC 
increased the survival of hippocampal neurons follow-
ing global brain ischemia in gerbils, and this protection 
was associated with reduced caspase-1 expression. In 
several models of neuronal injury, MIN was found to be 
protective against Huntington’s disease, traumatic brain 
injury and Parkinson’s disease by regulating caspase-1 
and/or caspase-3 expression [31–33]. These findings 
suggested that the anti-apoptotic effects of tetracyclines 
were mediated via inhibition of caspase expression and 
by mitochondrial stabilization. Although the authors [30] 
expressed their view that DC might possibly exhibit simi-
lar effects, no report exists till date.
Earlier literature showed that DC possessed non-
antibiotic properties including Fas/Fas Ligand (FasL)-
mediated apoptosis against several tumor types in the 
concentration range of 10–40 µg/mL. However, the effect 
of DC in apoptotic signaling at much low concentrations 
was not studied. Here we report that the low concentra-
tions of DC significantly attenuated FasL-induced apop-
tosis in HeLa cells by inhibition of caspase activation via 
FasL-induced extrinsic pathway.
Results
Effect of DC on FasL‑induced apoptosis in HeLa and NIH3T3 
cells
The effects of DC at increasing concentrations (0.01–
16  μg/mL) on FasL-induced apoptosis in HeLa and 
NIH3T3 cells measured by MTT assay were shown 
(Fig.  1). HeLa and NIH3T3 cells were pretreated with 
DC at indicated concentrations (0.01–16  μg/mL) for 
12 h with or without FasL (50 or 100 ng/mL) treatment 
for 24 h. FasL induced significant reduction in cell viabil-
ity at both 50 and 100 ng when compared to the control 
groups. Treatment with DC at low concentrations up to 
0.5  µg/mL significantly and concentration dependently 
inhibited FasL-induced cell death in HeLa cells (Fig. 1a) 
and these effects were also confirmed by crystal vio-
let assay (Additional file  1: Figure S1). However, DC at 
concentrations ranging from 4 to 16  µg/mL enhanced 
the FasL-induced cell death, reaching to a maximum at 
16  µg/mL concentration. Similar pattern was observed 
with DC in FasL-induced cell death in NIH3T3 cells 
(Fig.  1b). Further to understand the effect of low dose 
of DC on FasL-induced cell death in other cancer cells 
we performed similar experiments using cancer cell 
lines such as MDA-MB-231 (human breast adenocarci-
noma cells), LNCap (human prostate adenocarcinoma 
cells), U-87 MG (human glioblastoma cells), and TXM-1 
(human melanoma cells). Although FasL-induced cell 
death was observed in other cancer cells lines, and DC 
attenuated this cell death the results were not signifi-
cant at tested doses (Additional file  2: Figure S2). FasL-
induced apoptotic cell death was significantly attenuated 
by low dose of DC (0.5 µg/mL) in only HeLa cancer cells 
when compared with the effects observed in other cancer 
cells.
Effect of tetracycline and MIN on FasL‑induced apoptosis 
in HeLa cells
To investigate the effect of tetracycline and MIN on FasL-
induced apoptotic cell death, tetracycline and MIN at 
various concentrations (0.01–16 µg/mL) were incubated 
with FasL (50  ng/mL) in HeLa cells. Cell viability was 
measured by MTT assay. It was observed that both tetra-
cycline (Fig. 1c) and MIN (Fig. 1d) showed similar pattern 
like DC. However, the concentration required to inhibit 
the FasL-induced cell death by tetracycline and MIN was 
much higher compared to the effect observed by DC 
(0.5 µg/mL). These results suggest that DC was efficient 
and significant (p < 0.01 at 0.5 µg/mL) in inhibiting the 
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FasL-induced apoptotic cell death in HeLa cells when 
compared to tetracycline and MIN.
Effect of DC on cisplatin‑ and oxidative stress 
(H2O2)‑induced apoptosis
Cisplatin and oxidative stress can cause cell death via 
intrinsic apoptotic pathway. Thus, to evaluate the effect 
of DC on intrinsic apoptosis, we used cisplatin- and 
H2O2-induced apoptosis models in HeLa cells. HeLa cells 
were incubated with various concentrations of DC with 
or without cisplatin or H2O2. Cell viability was meas-
ured by MTT assay. As shown in Fig. 2, H2O2 (1.5 mM) 
and cisplatin (40  µM) induced significant apoptotic cell 
death in HeLa cells. However, treatment with DC at 
various concentrations (0.01–16 µg/mL) in the presence 
of H2O2 (Fig. 2a) or cisplatin (Fig. 2b) did not show any 
improvement in cell viability in HeLa cells. These results 
indicated that DC at low concentrations did not influ-
ence the oxidative stress and cisplatin-mediated intrinsic 
apoptotic pathway, but inhibited the FasL-induced apop-
totic cell death via extrinsic pathway.
Effect of low concentrations of DC on FasL‑induced 
morphological changes using DAPI staining
Initially, to select optimum concentrations of DC and 
FasL we performed the cell viability assay using MTT. We 
found that 0.5 µg/mL of DC did not exhibit any signs of 
toxicity but inhibited FasL-induced cytotoxicity signifi-
cantly in HeLa cells. Also 50 ng/mL of FasL showed opti-
mum (>45%) cytotoxicity (data not shown). Therefore for 
further apoptotic related experiments we used 0.5 µg/mL 
of DC and 50 ng/mL of FasL, respectively.
Fig. 1 Effect of DC and other tetracyclines (TC and MIN) on FasL-induced apoptotic cell death. Cells were pretreated with indicated concentrations 
(0–16 µg/mL) of DC, TC and MIN for 12 h with or without FasL (50 or 100 ng/mL) for 24 h. The metabolic activity was measured by the MTT assay. 
Each point represents the mean ± SEM (n = 3). a Effect of DC on FasL-induced cell viability in HeLa cells. b Effect of DC on FasL-induced cell viability 
in NIH3T3 cells. c Effect of TC on FasL-induced cell viability in HeLa cells; d effect of MIN on FasL-induced cell viability in HeLa cells. The significance 
was determined by Student’s t-test (n = 3). #p < 0.05, compares with control group. *p < 0.05 and p < 0.01, compared with FasL treated groups. DC 
doxycycline, TC tetracycline, MIN minocycline.
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Further to understand the effect of DC on FasL-
induced apoptosis morphologically in HeLa cells, we 
performed the DAPI staining. As shown in Fig.  3a, 
the nuclei of untreated control, DC treated alone and/
or FasL-treated cells were stained with DAPI solution. 
Results revealed that control cells (Fig.  3a, i) and DC 
(0.5  µg/mL) treated cells (Fig.  3a, ii) displayed intact 
nuclear structure while cells treated with FasL (50  ng/
mL) displayed apoptotic morphological characteristics, 
such as chromatin condensation and nuclear fragmen-
tation in HeLa cells (Fig.  3a, iii). However, treatment 
with DC (0.5 µg/mL) to FasL treated cells restored the 
cell viability and morphological changes in HeLa cells 
(Fig.  3a, iv). Quantification data from counting over 
200 cells (n = 3) revealed that FasL treated at 50 ng/mL 
induced cell death up to 50% (p  <  0.05) and treatment 
with DC inhibited the cell death significantly (p < 0.05, 
Fig. 3b).
In addition, nucleosomal DNA ladder formation by 
1.2% agarose gel electrophoresis was observed in HeLa 
cells treated with DC and/or FasL for 24  h. The results 
indicated that treatment with DC (0.5 µg/mL) alone did 
not affect the overall cell viability and FasL (100 ng/mL) 
alone treated cell showed DNA fragmentation. However, 
DC treatment to cells in the presence of FasL inhibited 
apoptosis (Fig.  3c). We further analyzed the degree of 
apoptotic cell death by Flow Cytometer. Cells treated 
with both DC and FasL resulted in inhibition of accu-
mulation of HeLa cells at the sub-G1 phase (Fig.  3d). 
These data suggested that DC has ability to inhibit FasL-
induced apoptosis. Further, percentages of cells in each 
phase were shown in Table 1.
Effect of low concentration of DC on caspase inhibition
Caspases are well known to serve as an important media-
tor of apoptosis in extrinsic pathway. Therefore, to gain 
further insight into the mechanism by DC in inhibiting 
FasL-induced apoptosis, HeLa cells were pretreated with 
DC (0.5  µg/mL) before FasL (50  ng/mL) treatment for 
24  h. Cell lysate was used to measure the expression of 
FLIP-L, pro-caspase-8, -3, PARP1, and BID. As shown 
in Fig. 4, treatment of cells with DC has no effect on the 
expression levels of Fas-signaling pathway related pro-
teins except FLIP-L known to inhibit FasL-induced apop-
tosis. Treatment of cells with DC and FasL attenuated 
FasL-induced activation of caspase-8 and caspase-3. The 
relative band intensity of FLIP-L, pro-caspase 8, pro-cas-
pase 3, PARP1 and BID, were measured by densitometric 
analysis and normalized with that of GAPDH (Fig.  4b). 
Taken together, as observed in Fig.  1a, low dose of DC 
treatment attenuated FasL-induced apoptosis in HeLa 
cells.
Discussion
The present study reported for the first time that low 
concentrations of DC inhibited FasL-induced apoptosis 
in HeLa cells in several aspects. DC is a broad-spectrum 
antibiotic used clinically for over six decades. DC acts as 
such at the ribosomal level where it interferes with pro-
tein synthesis in prokaryotic cells. Recently, DC has been 
shown to possess anti-tumor functions, such as inhibition 
of tumor proliferation, invasion, metastasis as well as the 
induction of apoptosis [22, 23]. Reports from earlier stud-
ies related to the non-antibiotic properties of DC includ-
ing apoptosis showed that DC in the concentration range 
Fig. 2 Effect of DC on hydrogen peroxide (H2O2)—or cisplatin-induced apoptotic cell death in HeLa cells. a HeLa cells were pretreated with 
indicated concentrations of DC (0.01–16 µg/mL) for 12 h with or without H2O2 (1.5 mM) for 24 h. b HeLa cells were pretreated with indicated 
concentrations of DC (0.01–16 µg/mL) for 12 h with or without cisplatin (40 µM) for 24 h. The cell viability was measured by the MTT assay. Each 
point represents the mean ± SEM (n = 3). The significance was determined by Student’s t-test. #p < 0.05 when compared with control group. $No 
significant difference when compared with H2O2 or cisplatin treated groups. DC doxycycline.
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of 10–40  µg/mL inhibited proliferation and induced 
apoptosis in several cancer cell lines [18, 20, 29, 34–36]. 
However, studies involving low concentrations of DC and 
its effect on apoptotic signaling were not elucidated. In 
the present investigation, we treated low concentrations 
of DC than commonly used and observed that DC at low 
concentrations inhibited FasL-induced apoptosis in HeLa 
cells.
FasL is a known inducer of apoptosis and is important 
in the regulation of several aspects of the immune system, 
Fig. 3 Effect of DC on morphological studies, DNA fragmentation and cell cycle arrest in FasL- induced apoptotic cell death in HeLa cells. HeLa cells 
were treated with indicated concentrations of DC (0.5 µg/mL) and FasL (50 ng/mL) as described in the methods. a The cells were fixed and stained 
with DAPI solution. The stained nuclei were the observed under a fluorescent microscope (×400). b The percentage of apoptotic cells was quanti-
fied. c DNA fragmentation assay. Same amount of genomic DNA (3 µg) extracted from cells was separated by 2.0% agarose gel electrophoresis, and 
visualized under UV light after staining with EtBr. Marker indicates a size marker of the DNA ladder. d To evaluate the degree of apoptosis reduced 
by DC, cells were evaluated by Flow Cytometry for sub-G1 DNA content (hypodilpoid DNA), which represents the cells undergoing apoptotic DNA 
degradation. Data are the mean ± SEM (n = 3). The significance was determined by Student’s t-test. #p < 0.05 compared with control group and 
**p < 0.01, compared with FasL treated group. DC doxycycline.
Table 1 Percentage of cells in different cell cycle phases in FasL-induced HeLa cells treated with DC
Percentages of cells in each phase were shown. Data are represented as mean ± SEM (n = 3). 
# p < 0.05 compared with DC treated cells and * p < 0.05 compared with FasL treated cells using students t test.
Control (%) DC 0.5 µg/mL (%) FasL 50 ng/mL (%) DC 0.5 µg/mL + FasL 50 ng/mL (%)
Sub-G1 9.67 ± 0.89 9.29 ± 0.42 62.74 ± 3.84# 39.39 ± 1.58*
G1 phase 52.15 ± 2.54 56.59 ± 2.86 22.54 ± 1.64# 37.09 ± 2.18*
S phase 6.44 ± 1.03 7.86 ± 1.84 5.34 ± 0.68 12. 42 ± 1.04*
G2 phase 18.77 ± 1.04 17.93 ± 2.01 11.33 ± 1.26# 19. 74 ± 1.93*
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including cytotoxic killing of cells potentially harmful to 
the organism such as virus-infected or tumor cells. DC at 
low concentrations (0.01–2 µg/mL) increased the cell via-
bility significantly in FasL-induced cytotoxicity in cancer 
cell lines HeLa and NIH3T3 fibroblast cell lines. However 
at higher concentrations (4–16 µg/mL), DC enhanced the 
FasL-induced apoptotic cell death which was in agree-
ment with the earlier studies [29, 34, 36]. Similar effects 
were observed with low concentrations of tetracycline 
and MIN, provided the anti-apoptotic effects were not 
significant as shown by DC in FasL-induced HeLa cells 
at similar concentrations. These results suggested that 
DC might be specific in significantly ameliorating Fas/
FasL- mediated apoptosis. Although, the results depicted 
in this study showed the apoptotic level at one time point 
(12  h interval), examining the process of apoptosis at 
various time intervals might still deliver a clear picture in 
evaluating the changes during the process of apoptosis.
Apoptosis can be induced by diverse stimuli including 
reactive oxygen species (ROS) or cisplatin. H2O2 induces 
apoptosis by intrinsic pathway triggered by the release of 
Cyt c from mitochondria and results in the activation of 
the initiator caspase-9 which then cleaves and activates 
caspase-3 [37, 38]. Cisplatin, which crosslinks DNA in 
Fig. 4 Inhibitory effect of low concentration of DC on the FasL-induced caspases cleavage in HeLa cells. HeLa cells were treated with the indicated 
concentrations of DC (0.5 µg/mL) and FasL (50 ng/mL) as described in the methods. a The cells were lysed and then cellular proteins were sepa-
rated by sodium dodecyl sulfate (SDS)-polyacrylamide gels and transferred onto nitrocellulose membranes. The membranes were probed with 
the indicated antibodies. Proteins were visualized using an enhanced chemiluminescence (ECL) detection system. GAPDH was used as an internal 
control. b Quantification of protein expression levels of FLIP-L, pro-caspase 8, pro-caspase 3, PARP1 and BID normalized to GAPDH. Data are the 
mean ± SEM (n = 3). The significance was determined by Student’s t-test. #p < 0.05 compared with DC group. *p < 0.05 and **p < 0.01, compared 
with FasL treated group. NS not significant compared with DC treated group, DC doxycycline.
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different pathways in turn activate apoptosis when repair 
proves impossible. In our present study, DC treated at 
indicated concentrations (0.01–16 µg/mL) did not influ-
ence the apoptotic cell death induced by H2O2 or cispl-
atin in HeLa cells. This further supports our notion that 
DC might act specifically via FasL-induced extrinsic 
apoptotic pathway.
Further, the morphological changes like chroma-
tin condensation of nuclei and DNA fragmentation in 
FasL-induced in HeLa cells was inhibited markedly sug-
gesting that low concentration of DC treatment (0.5 µg/
mL) exhibited anti-apoptotic properties. Flow cytomet-
ric analysis in HeLa cells revealed that FasL induction 
for 24 h decreased the cells at the G1-S phase of the cell 
cycle. However treatment with low concentration of DC 
(0.5 µg/mL) attenuated the decreased cell percentage and 
reduced the portion of apoptotic cells.
It was well documented that oligomerization of Fas 
via binding of its cognate ligand FasL, induces a signal-
ing cascade that culminates in the controlled degrada-
tion of cellular components [39]. The apical caspase-8 
and caspase-9, together with the downstream effector 
caspase-3, have been documented to be crucial players 
in the mediation of death receptor-induced apoptosis 
[40]. In our study, the suppression of FasL-induced pro-
caspase 8 and pro-caspase-3 protein expressions in HeLa 
cells was attenuated by treatment with low concentra-
tion of DC (0.5 µg/mL) suggesting that the effect of DC 
was mediated by the inhibition of caspase activation via 
FasL-induced extrinsic pathway. This might be attributed 
to a marked over-expression of FLIP-L observed by DC 
treatment.
Conclusion
Our study was the first to demonstrate that low concen-
tration of DC suppressed FasL-induced extrinsic apop-
tosis rather than cisplatin-induced intrinsic apoptosis by 
inhibition of caspase activation in HeLa cells.
Methods
Reagents
Dulbecco’s Modified Eagle’s Medium (DMEM), fetal 
bovine serum (FBS), penicillin and streptomycin were 
purchased from Hyclone (Logan, UT, USA). 3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bro-
mide (MTT), 4′, 6-diamidino-2-phenylindole (DAPI), 
FasL, cisplatin, and all other chemicals were purchased 
from Sigma Aldrich Co. (MO, USA). The antibodies of 
PARP1 (cat # 9542), FLIP-L (cat # 8510), BID (cat # 8762), 
Caspase-3 (cat # 9668), -8 (cat # 9746), and GAPDH (cat 
# 2118) were purchased from Cell Signaling Technology 
Inc. (MA, USA).
Cell culture
The cancer cell lines HeLa, MDA-MB-231 (human breast 
adenocarcinoma cells), LNCap (human prostate adeno-
carcinoma cells), U-87 MG (human glioblastoma cells), 
TXM-1 (human melanoma cells) and the fibroblast cell 
lines NIH3T3 were obtained from the American Type 
Culture Collection (ATCC, MD, USA) and maintained 
in DMEM supplemented with 10% heat-inactivated FBS 
and antibiotics (100 U/mL of penicillin, 100  μg/mL of 
streptomycin) in 5% CO2, 95% air and humidified atmos-
phere at 37℃.
MTT and Crystal Violet assay
Cell viability was determined by MTT and Crystal Violet 
assay. HeLa cell and NIH3T3 cell were plated in triplicate 
at the concentration of 2.5  ×  105 cells/well on 96-well 
plate and pretreated with various concentrations of DC, 
tetracycline and MIN, respectively for 12 h and incubated 
with or without FasL for another 24 h. Similar conditions 
were followed for evaluating the effect of DC at various 
concentrations in hydrogen peroxide (H2O2; 1.5  mM)- 
and cisplatin (40 μM)-induced cytotoxicity in HeLa cells. 
For MTT assay, the medium was discarded and 100 μL 
of DMEM medium containing MTT (0.5  mg/mL) was 
added to each well, followed by incubation for 2 h at 37°C 
After incubation, the medium were discarded, 100  μL 
dimethyl sulfoxide (DMSO) was added to dissolve the 
MTT formazan. For Crystal Violet assay, the medium 
was discarded and stained with 30 μL of 0.05% Crystal 
Violet in 70% Methanol to each well, followed by incuba-
tion for 30 min at room temperature. The optical density 
for MTT and Crystal Violet assay were measured at 550 
and 570 nm, respectively.
DAPI staining
After treatment with DC or FasL, the cells were har-
vested, washed in ice-cold PBS and fixed with 4% para-
formaldehyde in PBS for 10  min at room temperature. 
The fixed cells were washed with PBS and stained with a 
DAPI (300 nM) solution containing 0.2% TritonX-100 for 
10 min at room temperature. The cells were washed twice 
with PBS and analyzed via a fluorescence microscope 
(Carl Zeiss, Oberkochen, Germany).
DNA fragmentation assay
After treatment with DC or FasL, the cells were lysed in 
a buffer containing 10  mM Tris–HCl, pH 7.4, 150  mM 
NaCl, 5  mM EDTA, and 0.5% Triton X-100 for 20  s at 
room temperature. The lysates were vortexed and cleared 
by centrifugation at 3,000  rpm for 30  min at 4°C. The 
DNA in the supernatant was extracted using ethanol and 
analyzed electrophoretically on 2.0% agarose gels.
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Distribution of cells in the cell cycle phases
Pretreated cells with DC or FasL were collected, washed 
with cold PBS and fixed in 75% ethanol at 4°C overnight. 
Cells were stained with PI (2  µg/mL) in PBS contain-
ing 0.2% triton X-100 for 20  min at room temperature. 
Flow cytometric analyses were carried out using a flow 
cytometer.
Western blotting
After treatment of DC or FasL, cells were harvested and 
washed twice in PBS at 4°C. Total cells were lysed in lysis 
buffer [40 mM Tris (pH8.0), 120 mM NaCl, 0.5% NP-40, 
0.1 mM sodium orthovanadate, 2 μg/mL aprotinin, 2 μg/
mL leupeptin, and 100 μg/mL phenymethylsulfonyl fluo-
ride]. Equal amounts of protein extracts were subjected 
to 10–12% SDS–polyacrylamide gels, and transferred to 
Nitrocellulose membrane. Immunoblot analyses were per-
formed using rabbit anti-mouse antibodies that recognize 
FLIP-L (1:1,000), Caspase 8 (1:500), Caspase 3 (1:500), 
PARP1 (1:1,000), BID (1:500), and GAPDH (1:1,000) 
in PBST buffer (80  mM Na2HPO4; 20  mM NaH2PO4; 
100  mM NaCl; 0.1% Tween-20) +  1% BSA, followed by 
incubation with secondary antibody sheep anti-mouse or 
anti-rabbit HRP (1:2,500) in the same buffer. Detection 
was performed by enhanced chemiluminescence (ECL) 
kit according to the manufacturer’s instructions (Amer-
sham Corp., Arlington Heights, IL, USA).
Statistical analysis
Data are summarized as mean ± SEM (n = 3). The statis-
tical analysis of the results was performed by the students 
t test using GraphPad Sigma-Plot Software (Systat Soft-
ware Inc, CA, USA). In all experiments, p values less than 
0.05 were considered statistically significant.
Abbreviations
DC: doxycycline; FasL: Fas Ligand; Cyt c: cytochrome c; MIN: minocycline; 
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; DAPI: 
6-diamidino-2-phenylindole.
Additional files
Additional file 1: Figure S1. Effect of DC on FasL-induced apoptotic cell 
death. HeLa cells were pretreated with indicated concentrations (0.01-16 
µg/mL) of DC for 12h with or without FasL (150 ng/ml) for 24h. The cell 
viability was measured by the crystal violet assay. Each point represents 
the mean±S.E.M. (n=3). The significance was determined by Student’s 
t-test. #p < 0.05, compares with control groups. *p < 0.05, compared with 
FasL treated groups. DC: Doxycycline.
Additional file 2: Figure S2. Effect of DC on FasL-induced apoptotic 
cell death in many cancer cell lines. Cells were pretreated with indicated 
concentrations (0.5 µg/mL) of DC for 12h with or without FasL (100 ng/
ml) for 24h. The cells viability were measured by the MTT assay. Tested cell 
lines were MDA-MB-231 (human breast adenocarcinoma cells), LNCap 
(human prostate adenocarcinoma cells), U-87 MG (human glioblastoma 
cells), and TXM-1 (human melanoma cells). Each point represents the 
mean ± S.E.M. (n=3).
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